Biologic switching is common in children and young people with juvenile idiopathic arthritis (JIA) a UK study shows, with no evidence of a benefit of switching classes of biologic for subsequent treatment. More than one-fifth of young patients with polyarticular-course JIA started a second biologic when a first tumour necrosis factor inhibitor (TNFi) was ineffective ...
Biologic switching in JIA: does changing class affect outcomes?
By Emma Wilkinson
18 Mar 2020